Recently, it has been found that when KRAS-driven non-small cell lung cancer (NSCLC) patients were treated with epidermal growth factor receptor (EGFR) targeting therapeutic approach, significantly higher expression of CXCR7 were observed and MAPK (ERK1/2) signaling was activated, implying that EGFR and CXCR7 had a crucial interaction in NSCLC [37]. The gene discussed is MAPK3; the disease is non-small cell lung carcinoma.